Transgenic Group Inc. (TYO:2342)

Market Cap	3.85B +36.7%
Revenue (ttm)	13.17B +1.3%
Net Income	-77.00M
EPS	-4.62
Shares Out	16.65M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	134,700
Open	231.00
Previous Close	231.00
Day's Range	227.00 - 237.00
52-Week Range	150.00 - 487.00
Beta	0.41
Analysts	n/a
Price Target	n/a
Earnings Date	May 13, 2026

About Transgenic Group

Transgenic Group Inc. develops, distributes, and licenses genetically modified animals and antibodies in Japan. It operates through Drug Discovery Support Business and Investment and Consulting Business segments. The company provides glycan synthesis and analysis services; non-clinical studies for pharmaceuticals, foods, cosmetics, chemical substances, etc., as well as various safety tests for foods, and pharmaceutical agents; and support for bioequivalence test, including clinical trials, pharmacokinetic measurements, and the preparation of cl...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1998
• Employees: 241
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 2342

Financial Performance

In fiscal year 2026, Transgenic Group's revenue was 13.17 billion, an increase of 1.30% compared to the previous year's 13.01 billion. Losses were -77.00 million, -92.93% less than in 2025.